SWTX SpringWorks Therapeutics Inc

Price (delayed)

$36.83

Market cap

$2.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.15

Enterprise value

$2.62B

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks ...

Highlights
SWTX's debt is down by 7% since the previous quarter and by 7% year-on-year
SWTX's quick ratio has dropped by 53% year-on-year but it is up by 6% since the previous quarter
SpringWorks Therapeutics's equity has increased by 12% YoY but it has decreased by 9% QoQ
The net income has contracted by 17% YoY and by 4.3% from the previous quarter

Key stats

What are the main financial stats of SWTX
Market
Shares outstanding
74.09M
Market cap
$2.73B
Enterprise value
$2.62B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.79
Price to sales (P/S)
102.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
98.91
Earnings
Revenue
$26.45M
EBIT
-$339.07M
EBITDA
-$335.16M
Free cash flow
-$244.89M
Per share
EPS
-$5.15
Free cash flow per share
-$3.32
Book value per share
$7.69
Revenue per share
$0.36
TBVPS
$8.9
Balance sheet
Total assets
$656.83M
Total liabilities
$89.39M
Debt
$6.56M
Equity
$567.44M
Working capital
$402.88M
Liquidity
Debt to equity
0.01
Current ratio
6.85
Quick ratio
6.57
Net debt/EBITDA
0.33
Margins
EBITDA margin
-1,267%
Gross margin
93.9%
Net margin
-1,281.8%
Operating margin
-1,358.1%
Efficiency
Return on assets
-57.3%
Return on equity
-66.5%
Return on invested capital
-82.4%
Return on capital employed
-57.7%
Return on sales
-1,281.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SWTX stock price

How has the SpringWorks Therapeutics stock price performed over time
Intraday
-2.36%
1 week
-11.97%
1 month
1.97%
1 year
24.17%
YTD
0.9%
QTD
-2.23%

Financial performance

How have SpringWorks Therapeutics's revenue and profit performed over time
Revenue
$26.45M
Gross profit
$24.83M
Operating income
-$359.25M
Net income
-$339.07M
Gross margin
93.9%
Net margin
-1,281.8%
SWTX's net margin has surged by 79% since the previous quarter
SWTX's operating margin has soared by 78% from the previous quarter
The operating income has contracted by 21% YoY and by 4.7% from the previous quarter
The net income has contracted by 17% YoY and by 4.3% from the previous quarter

Growth

What is SpringWorks Therapeutics's growth rate over time

Valuation

What is SpringWorks Therapeutics stock price valuation
P/E
N/A
P/B
4.79
P/S
102.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
98.91
SpringWorks Therapeutics's equity has increased by 12% YoY but it has decreased by 9% QoQ
The P/B is 11% above the last 4 quarters average of 4.3 but 6% below the 5-year quarterly average of 5.1

Efficiency

How efficient is SpringWorks Therapeutics business performance
SWTX's ROS has soared by 79% from the previous quarter
The ROE has contracted by 15% YoY
SWTX's ROA is down by 11% YoY

Dividends

What is SWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SWTX.

Financial health

How did SpringWorks Therapeutics financials performed over time
SWTX's quick ratio has dropped by 53% year-on-year but it is up by 6% since the previous quarter
The company's current ratio has shrunk by 52% YoY but it rose by 7% QoQ
SWTX's debt is 99% smaller than its equity
SpringWorks Therapeutics's equity has increased by 12% YoY but it has decreased by 9% QoQ
SWTX's debt is down by 7% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.